Centennial Bank’s Rocket Pharmaceuticals RCKT Stock Holding History

Centennial Bank’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-500	Closed	-$9.79K	–	334
2022 Q4	$9.79K	Buy	+500	New	+$9.21K	0.01%	282

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Centennial Bank's RCKT Position: Q1 2023 in Review

Centennial Bank sold out of Rocket Pharmaceuticals (RCKT) in Q1 2023, closing a stake of 500 shares — an estimated $9.79K sold.

Centennial Bank first reported a position in RCKT in Q4 2022 and held it in 1 quarter. The position peaked at $9.79K in Q4 2022. 163 funds tracked by Wall St. Rank hold RCKT as of Q1 2023.

Centennial Bank reported no remaining Rocket Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Centennial Bank sold 500 Rocket Pharmaceuticals shares in Q1 2023, an estimated $9.79K.
Centennial Bank first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Centennial Bank's Rocket Pharmaceuticals position peaked at $9.79K in Q4 2022.
163 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2023.

Based on Centennial Bank's 13F filing for Q1 2023, filed 28 Aug 2024.